Company intelligence / Profile preview

ImmVirX

New Lambton Heights, New South Wales, Australiaimmvirx.com ↗

Ownership: Private
Development stage: Phase 1

Overview

ImmVirX’s lead program IVX037 has shown notable tumor reductions and evidence of abscopal activity as a monotherapy in early clinical studies. The Phase 1b trial now includes combination with anti-PD‑1 therapy. Additional candidates are advancing toward the clinic.

Therapeutic areas: Oncology
Modalities: Oncolytic RNA virusesImmunotherapies (oncolytic viral immunotherapy)
Industry: Biotech

Drug pipeline

2 assets

IVX037

1 more asset in the full pipeline.

Request access →

Partnerships

Innovent Biologics – collaboration for Phase Ib study combining IVX037 with Innovent’s anti-PD‑1 therapy TYVYT®.

Beyond the preview

Go deeper on ImmVirX.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ImmVirX.

Explore the full profile